Market Research Logo

Global Constipation Market: Industry Analysis & Outlook (2017-2021)

Global Constipation Market: Industry Analysis & Outlook (2017-2021)

Constipation is a chronic medical condition which makes a person unable to pass fecal content properly. In this condition, the stool is often dry, hard and painful to pass. Bowel movements vary person to person but, if the bowel movement is missing for more than 3 days in adults and 4 days in children, then it is considered as constipation. Constipation can be of three types; irritable bowel syndrome-constipation (IBS-C), chronic idiopathic constipation and opioid-induced-constipation (OIC).

The U.S. is a major contributor to the global constipation market supported by rising opioid usage among chronic disease patients and increasing prescription drugs volumes. The U.S. is likely to experience further growth in constipation market with increasing ageing population and rapid development of new drugs in the market.

There exist vast opportunities for prescription drugs in the constipation market. However, OTC drugs and laxatives are generally used for treating constipation, patients and physicians have started recognizing the importance of branded drugs. Future growth of the constipation market is based on continued growth of prescription therapies to treat constipation, increased research and development of novel drugs by biopharmaceutical companies, increasing patient and physician awareness of effective prescription alternatives to Over-the-Counter medications.

The global constipation market is expected to grow in future with rising constipation prevalence, increasing ageing population, rise in health expenditure, mounting spinal cord injury patient population, growing spending on medicines and pharmaceutical R&D expenditure. Key trends of this market include progressing drugs under pipeline and adoption of unhealthy lifestyle. However, there are some factors which can hinder growth of the market including stringent regulations and low awareness of prescription drugs.

The report “Global Constipation Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Japan, China and Europe. The report profiles the key players of the market including Ironwood Pharmaceuticals Inc., Sucampo Pharmaceuticals Inc., Synergy Pharmaceuticals Inc. and ARDELYX Inc.


1. Overview
1.1 Constipation
Table 1: Types of Constipation
Table 2: Current Treatment Options for Constipation
2. Constipation Market Analysis
2.1 The U.S.
2.1.1 The U.S. Constipation Market by Value
Table 3: The U.S. Constipation Market by Value (2012-2016)
2.1.2 The U.S. Constipation Market by Type
Table 4: The U.S. Constipation Market by Type (2012-2016)
2.1.3 The U.S. Constipation Market Forecast by Value
Table 5: The U.S. Constipation Market Forecast by Value (2017-2021)
2.1.4 The U.S. Constipation Market Forecast by Type
Table 6: The U.S. Constipation Market Forecast by Type (2017-2021)
2.1.5 The U.S. Constipation Market by Drug
Table 7: The U.S. Constipation Market by Drug (2016/2021)
2.1.6 The U.S. Constipation Branded Drugs Prescription Volume
Table 8: The U.S. Constipation Branded Drugs Prescription Volume (2012-2016)
2.1.7 The U.S. Constipation Branded Drug Prescription Volume by Type
Table 9: The U.S. Constipation Branded Drug Prescription Volume by Type (2012-2016)
2.1.8 The U.S. Constipation Patient Population Forecast
Table 10: The U.S. Constipation Patient Population Forecast (2016-2021
2.2 Europe
2.2.1 Europe CIC Patient Population Forecast
Table 11: Europe CIC Patient Population Forecast (2016-2021
2.2.2 Europe IBS-C Patient Population Forecast
Table 12: Europe IBS-C Patient Population Forecast (2016-2021)
2.2.3 Europe OIC Patient Population Forecast
Table 13: Europe OIC Patient Population Forecast (2016-2021)
2.2.4 Europe Plecanatide Sales Forecast
Table 14: Europe Plecanatide Sales Forecast (2018-2021)
2.3 Japan
2.3.1 Japan Constipation Patient Population Forecast
Table 15: Japan Constipation Patient Population Forecast (2016-2021)
2.3.2 Japan Amitiza Sales Forecast
Table 16: Japan Amitiza Sales Forecast (2016-2021)
2.4 China
2.4.1 China Constipation Patient Population Forecast
Table 17: China Constipation Patient Population Forecast (2016-2021)
2.4.2 China Amitiza Sales Forecast
Table 18: China Amitiza Sales Forecast (2018-2021)
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Rising Prevalence of Constipation
3.1.2 Increasing Ageing Population
Table 19: Global Ageing Population (2012-2016)
3.1.3 Rising Healthcare Expenditure
Table 20: Global Healthcare Expenditure per Capita (2012-2016)
3.1.4 Rising Spending on Medicines Worldwide
Table 21: Global Spending on Medicines (2012-2016)
3.1.5 Rising Cases of Spinal Cord Injury
Table 22: Global Spinal Cord Injury Patient Population (2012-2016)
3.1.6 Increasing Pharmaceutical R&D Spending
Table 23: Global Pharmaceutical R&D Spending (2013-2016)
3.2 Key Trends & Developments
3.2.1 Progressing Drugs Under Pipeline
Table 24: Drugs under Development for Constipation (2016)
3.2.2 Adoption of Unhealthy Lifestyle
3.3 Challenges
3.3.1 Stringent Regulations
3.3.2 Low Awareness of Prescription Constipation Drugs
4. Competitive Landscape
4.1 Global Market
4.1.1 Revenue Comparison of Key Players
Table 25: Revenue Comparison of Key Players (2016)
4.1.2 Market Cap of Key Players
Table 26: Market Cap of Key Players (2016)
4.2 The U.S.
4.2.1 The U.S. Constipation Market Share by Company
Table 27: The U.S. Constipation Market Share by Company (2016)
4.2.2 The U.S. Constipation Market Share Forecast by Company
Table 28: The U.S. Constipation Market Share Forecast by Company (2021)
5. Company Profiles
5.1 Ironwood Pharmaceuticals Inc.
5.1.1 Business Overview
Table 29: Ironwood Pharmaceuticals Inc Revenue by Product (2016)
5.1.2 Financial Overview
Table 30: Ironwood Pharmaceutical Inc. Revenue and Net Loss (2012-2016)
5.1.3 Business Strategies
Table 31: Ironwood Pharmaceuticals Inc. R&D Expenditure (2014-2016)
5.2 Sucampo Pharmaceuticals Inc.
5.2.1 Business Overview
Table 32: Sucampo Pharmaceuticals Inc. Revenue by Product (2016)
5.2.2 Financial Overview
Table 33: Sucampo Pharmaceuticals Inc. Revenue and Net Income (2012-2016)
5.2.3 Business Strategies
Table 34: Sucampo Pharmaceuticals Inc. R&D Expenditure (2014-2016)
5.3 ARDELYX, Inc.
5.3.1 Business Overview
Table 35: ARDELYX, Inc. Drugs Under Pipeline
5.3.2 Financial Overview
Table 36: ARDELYX, Inc. Total Revenue and Net Loss (2012-2016)
5.3.3 Business Strategies
Table 37: ARDELYX, Inc. R&D Expenditure (2014-2016)
5.4 Synergy Pharmaceuticals, Inc
5.4.1 Business Overview
Table 38: Synergy Pharmaceuticals, Inc. Drugs Under Pipeline (2016)
5.4.2 Financial Overview
Table 39: Synergy Pharmaceuticals, Inc. Net Loss (2012-2016)
5.4.3 Business Strategies
Table 40: Synergy Pharmaceuticals, Inc. R&D Expenditure (2014-2016)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report